Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants.

[1]  D. Richman,et al.  Antiviral drug resistance. , 2006, Antiviral research.

[2]  T. Hien,et al.  Avian influenza A (H5N1) , 2005, Journal of Clinical Virology.

[3]  J. McKimm-Breschkin.  Management of Influenza Virus Infections with Neuraminidase Inhibitors , 2012, Treatments in respiratory medicine.

[4]  R. Webster,et al.  Detection of amantadine-resistant variants among avian influenza viruses isolated in North America and Asia. , 2005, Virology.

[5]  Xiyan Xu,et al.  Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern , 2005, The Lancet.

[6]  P. Ward,et al.  Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. , 2005, The Journal of antimicrobial chemotherapy.

[7]  R. Webster,et al.  Neuraminidase Inhibitor-Rimantadine Combinations Exert Additive and Synergistic Anti-Influenza Virus Effects in MDCK Cells , 2004, Antimicrobial Agents and Chemotherapy.

[8]  A. Monto,et al.  Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. , 2004, The Journal of infectious diseases.

[9]  Yoshihiro Kawaoka,et al.  oseltamivir: descriptive study , 2022 .

[10]  E. Korchagina,et al.  Synthesis of polymeric neoglycoconjugates based onN-substituted polyacrylamides , 1993, Glycoconjugate Journal.

[11]  H. Goto,et al.  High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. , 2003, The Journal of infectious diseases.

[12]  A. Monto,et al.  The role of antivirals in the control of influenza. , 2003, Vaccine.

[13]  D. Smee,et al.  Combination Treatment of Influenza A Virus Infections in Cell Culture and in Mice with the Cyclopentane Neuraminidase Inhibitor RWJ-270201 and Ribavirin , 2002, Chemotherapy.

[14]  F. Hayden,et al.  Perspectives on antiviral use during pandemic influenza. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[15]  Y. Guan,et al.  Universal primer set for the full-length amplification of all influenza A viruses , 2001, Archives of Virology.

[16]  K G Nicholson,et al.  Influenza: vaccination and treatment. , 2001, The European respiratory journal.

[17]  J. McKimm-Breschkin,et al.  Resistance of influenza viruses to neuraminidase inhibitors--a review. , 2000, Antiviral research.

[18]  Xiaowu Chen,et al.  Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor. , 2000, Current medicinal chemistry.

[19]  M. Matrosovich,et al.  Intergenic HA-NA interactions in influenza A virus: postreassortment substitutions of charged amino acid in the hemagglutinin of different subtypes. , 2000, Virus research.

[20]  N. Cox,et al.  Low incidence of rimantadine resistance in field isolates of influenza A viruses. , 1999, The Journal of infectious diseases.

[21]  A. Monto,et al.  Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. , 1999, The Journal of infectious diseases.

[22]  R. Webster,et al.  The Surface Glycoproteins of H5 Influenza Viruses Isolated from Humans, Chickens, and Wild Aquatic Birds Have Distinguishable Properties , 1999, Journal of Virology.

[23]  R. Webster,et al.  Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. , 1998, The Journal of infectious diseases.

[24]  J. McKimm-Breschkin,et al.  The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en. , 1998, Virology.

[25]  R. Webster,et al.  Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus , 1998, The Lancet.

[26]  R. Webster,et al.  How to overcome resistance of influenza A viruses against adamantane derivatives. , 1998, Antiviral research.

[27]  Leming,et al.  Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections , 1997 .

[28]  M B Eisen,et al.  Binding of the influenza A virus to cell-surface receptors: structures of five hemagglutinin-sialyloligosaccharide complexes determined by X-ray crystallography. , 1997, Virology.

[29]  R. Webster,et al.  Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en , 1996, Journal of virology.

[30]  R. Bethell,et al.  Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en , 1996, Antimicrobial agents and chemotherapy.

[31]  N. Cox,et al.  Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. , 1995, The Journal of infectious diseases.

[32]  F. Hayden,et al.  In vitro Inhibitory Effects of Combinations of anti-Influenza Agents , 1995 .

[33]  A. Golbraikh,et al.  Probing of the receptor-binding sites of the H1 and H3 influenza A and influenza B virus hemagglutinins by synthetic and natural sialosides. , 1993, Virology.

[34]  D. M. Ryan,et al.  Rational design of potent sialidase-based inhibitors of influenza virus replication , 1993, Nature.

[35]  P. Colman,et al.  The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor , 1992, Proteins.

[36]  M. Matrosovich,et al.  A solid-phase enzyme-linked assay for influenza virus receptor-binding activity. , 1992, Journal of virological methods.

[37]  Lawrence H. Pinto,et al.  Influenza virus M2 protein has ion channel activity , 1992, Cell.

[38]  F. Hayden,et al.  Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. , 1992, Current topics in microbiology and immunology.

[39]  Y Tateno,et al.  Comparison of complete amino acid sequences and receptor-binding properties among 13 serotypes of hemagglutinins of influenza A viruses. , 1991, Virology.

[40]  S. Cusack,et al.  Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid , 1988, Nature.

[41]  J. Skehel,et al.  The molecular basis of the specific anti‐influenza action of amantadine. , 1985, The EMBO journal.

[42]  I. Wilson,et al.  Single amino acid substitutions in influenza haemagglutinin change receptor binding specificity , 1983, Nature.

[43]  F. Hayden,et al.  Enhancement of activity against influenza viruses by combinations of antiviral agents , 1980, Antimicrobial Agents and Chemotherapy.

[44]  F. Hayden,et al.  Plaque inhibition assay for drug susceptibility testing of influenza viruses , 1980, Antimicrobial Agents and Chemotherapy.

[45]  R. Couch,et al.  Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice , 1980, Antimicrobial Agents and Chemotherapy.

[46]  M. Potier,et al.  Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate. , 1979, Analytical biochemistry.